Why the study?
What are the national dispensing volumes and population-level utilisation patterns of prolonged low-dose antithrombotic and anti-inflammatory therapies in Switzerland and Germany between 2022 and 2024?
What are the national dispensing volumes and population-level utilisation patterns of prolonged low-dose antithrombotic and anti-inflammatory therapies in Switzerland and Germany between 2022 and 2024?
Real-world population-level uptake of guideline-recommended intensified low-dose antithrombotic and anti-inflammatory therapies for coronary artery disease remains low relative to aspirin in both Germany and Switzerland, particularly in Switzerland.
Answers are grounded in this paper and cite their sources.
Patent proceedings supply no outcome data; leaves open real-world uptake of intensified antithrombotic regimens in CAD.
STUDY AIMS: Prolonged low-dose antithrombotic and anti-inflammatory therapies have been shown to reduce cardiovascular events and are guideline-recommended in patients with coronary artery disease at high ischaemic risk. However, their real-world dispensing patterns at the population level remain insufficiently characterised. This study aimed to quantify national dispensing volumes and compare the use of these therapies in Switzerland and Germany between 2022 and 2024. METHODS: We analysed national pharmaceutical delivery data from Switzerland and outpatient prescription data from Germany for low-dose monotherapy products containing aspirin (100 mg), clopidogrel (75 mg), prasugrel (5 mg and 10 mg), ticagrelor (60 mg and 90 mg), rivaroxaban (2.5 mg) and colchicine (0.5 mg in Germany, 1 mg in Switzerland). Drug utilisation was standardised as the number of tablets per 1000 persons per year. This metric reflects population-level exposure: based on epidemiological data indicating a substantial burden of cardiovascular disease and evidence that a relevant proportion of these patients may qualify for intensified long-term preventive therapy, dispensing volumes of long-term antithrombotic and anti-inflammatory therapies might be expected to reach a meaningful fraction of aspirin use (>10%). Values substantially below this illustrative threshold may suggest limited population-level uptake. RESULTS: Aspirin 100 mg was the most frequently dispensed drug in both Switzerland and Germany (both >8000 tablets/1000 persons/year). Clopidogrel ranked second in both countries. Ticagrelor (60 mg and 90 mg) was more frequently dispensed in Switzerland, whereas prasugrel 10 mg was more frequently dispensed in Germany. However, absolute use of both agents remained low (all <500 tablets/1000 persons/year). Rivaroxaban 2.5 mg was the only agent that showed a consistent increase over time (+54.4% Switzerland; +40.4% Germany), although overall dispensing remained modest (538-577 tablets/1000 persons/year). Colchicine use was low in both countries (124-163 tablets/1000 persons/year). Across both countries, the combined dosing-adjusted dispensing volume of intensified long-term antithrombotic and anti-inflammatory therapies was close to or below the illustrative 10% benchmark relative to aspirin use, reaching 10.1% in Germany and 4.5% in Switzerland, suggesting limited population-level uptake, particularly in Switzerland. CONCLUSION: Despite minor country-specific differences in cardiovascular disease prevalence, the observed dispensing patterns suggest that the population-level uptake of low-dose antithrombotic and anti-inflammatory therapies may be lower than expected when interpreted relative to aspirin.
No takes yet. Share an insight, caveat, or question.
Kunz et al. (2026) studied Thromboembolic disorder. Rivaroxaban was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: